Аннотация:Selective sodium-glucose cotransporter 2 (SGLT2) inhibitors are known to improve the cardiovascular outcome in patients with heart failure and type 2 diabetes. This study aimed to investigate the effects of SGLT2 inhibitor Empagliflozin on cardiac function after myocardial infarction (MI) in normoglycemic rats.